SNAPCHIP-AKT PATHWAY ACTIVATION
24 samples & 8 replicates
• • Akt-1 total & P-Ser473
• • Akt-2 total & P-Ser474
• • Akt-3 total & P-Ser472
• Akt P-Thr308
• • mTOR total & P-Ser2481
• • S6 total & P-Ser235/6

The SnapChip is perfectly suited to quickly and efficiently study the Akt pathway. The cross reaction-free, multiplex platform allows for a unique combination of assays, such as isoforms and phosphospecific antibodies, side-by-side.

About Akt Pathway
Akt is a subfamily of serine/threonine kinases (Protein Kinase B) that includes AKT1, AKT2, and AKT3. Akt resides in the cytosol in an inactive conformation, until the cell is stimulated leading to the activation of PI3K. Activation of PI3K converts plasma membrane phospholipids PIP2 to PIP3, leading to the recruitment of Akt to the membrane. Akt is then activated by phosphorylation by PDK1 and multiple catalytic proteins. To a lesser extent, Akt activation can occur trough other tyrosine or serine/threonine kinases, in response to heat shock or following an increase in calcium concentration. Once active, Akt translocates to the cytosol and nucleus, where it regulates (inhibitory or stimulatory) a wide range of proteins involved in critical cellular processes.
The Akt activation pathway regulates many targets involved in a variety of human diseases, making it a pathway of interest in medical research.
Cell Survival & Apoptosis
Cell Cycle Progression
Cell Migration
Glucose Metabolism
Cancer & Angiogenesis
Lysosome Biogenesis & Autophagy
Check out our posts

Parallex BioAssays in Alberta
Product show in Alberta Back in October, Sébastien Bergeron (CEO) was meeting and exchanging with scientists from the University of Alberta, in Alberta, from the

Movember Campaign- The month of Movember
“Each year since 2003, men from all over the world, grow their mustache for a whole month to raise awareness for prostate cancer, testicular cancer,

Special Event MaRS Discovery District
Special Event MaRS Discovery District On September 19th, is going to be the MaRS product show in Toronto. Our CEO won’t be able to make